Q-Line Biotech Ltd. is stepping into the public markets with a maiden book-building issue aiming to raise Rs 214.48 crore. Operating in the in-vitro diagnostics sector since 2013, the company builds, manufactures, and markets a broad array of medical reagents, point-of-care devices, consumables, and diagnostic equipment. Its core operations span clinical chemistry, hematology, immunodiagnostics, and molecular diagnostics. The business serves hospitals, medical colleges, and diagnostic service providers either directly or through a network of distributors.
During the pandemic, the firm expanded its product line via internal research and third-party partnerships to produce COVID-19 testing kits, including RT-PCR and RNA extraction products. It maintains technical collaborations with international firms to manufacture specific classes of regulated equipment under strict compliance standards. As of March 31, 2026, the company maintained 362 payroll employees, 223 contract personnel, and 19 research and development staff members working in specialized laboratories.
Structure and Pricing of the Offer
The initial public offering consists of 6,253,200 equity shares with a face value of Rs 10 each, offered within a price band of Rs 326 to Rs 343 per share. Investors must bid for a minimum lot of 800 shares, and in multiples of 400 shares thereafter. A simple calculation reveals that a single retail lot at the upper price band costs Rs 2,74,400. The issue represents 26.81% of the post-IPO paid-up capital. Prior to this main book-built offering, the company completed a pre-IPO placement of 800,000 shares in May 2026 at Rs 343 per share, securing Rs 27.44 crore.
The proceeds from the fresh issue are earmarked for specific corporate requirements. The firm plans to use Rs 93.50 crore to support working capital needs, Rs 90.00 crore to pay off or prepay certain borrowings, and direct the remainder toward general corporate purposes. Hem Securities Ltd. and Share India Capital Services Pvt. Ltd. are the joint lead managers for the issue, while Purva Sharegistry (India) Pvt. Ltd. acts as the registrar. Hem Finlease Pvt. Ltd. serves as the market maker and syndicate member. Shares are scheduled to list on the NSE SME Emerge platform.
Financial Performance and Valuation Metrics
A look at the financial statements shows top-line growth accompanied by bottom-line volatility. Total income moved from Rs 184.81 crore in FY23 to Rs 206.45 crore in FY24, and reached Rs 322.58 crore in FY25. Net profits during the same fiscal years were Rs 32.10 crore, Rs 34.44 crore, and Rs 28.13 crore respectively. For the nine-month period ending December 31, 2025, the firm posted a net profit of Rs 38.69 crore on a total income of Rs 236.50 crore. The dip in FY25 net profit followed an extraordinary item of Rs 16.97 crore, while the strong earnings reported in the subsequent nine-month stretch point to a sharp pre-IPO profit surge.
The company carries heavy financial obligations that warrant close examination. Total borrowings stood at Rs 242.57 crore as of December 31, 2025, alongside contingent liabilities of Rs 61.64 crore. The net asset value per share was reported at Rs 140.81 as of December 31, 2025, resulting in a price-to-book value ratio of 2.44 at the upper price band. If we attribute the annualized earnings for the first nine months of FY26 to the fully diluted post-IPO capital, the asking price reflects a price-to-earnings ratio of 15.51. Based on FY25 earnings, the P/E climbs to 28.44. The offer document lists no direct peers for comparison, making it difficult to benchmark the valuation against similar listed entities.
Investment Outlook
The valuation appears full when considering the sharp profit spike ahead of the public offering, which may face challenges in future quarters. Debt levels and contingent liabilities add an extra layer of risk that conservative investors should weigh carefully. However, the decision to channel a large portion of funds into debt reduction and working capital addresses immediate balance sheet pressures. The issue suits well-informed investors willing to park capital for a medium-to-long-term horizon while accepting the inherent risks of SME market listings.
Frequently Asked Questions
The company aims to mobilize Rs 214.48 crore by issuing 6,253,200 equity shares.
The price band is fixed at Rs 326 to Rs 343 per equity share.
The minimum application requires 800 shares, and bids can be made in multiples of 400 shares thereafter.
The company will use Rs 93.50 crore for working capital, Rs 90.00 crore for repayment or prepayment of certain borrowings, and the remaining amount for general corporate purposes.
The shares will be listed on the NSE SME Emerge platform.
The IPO is jointly lead managed by Hem Securities Ltd. and Share India Capital Services Pvt. Ltd.
The company earned a net profit of Rs 38.69 crore on a total income of Rs 236.50 crore for the 9M period ending December 31, 2025.
